



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Estimate of the incidence of bladder cancer in Africa

Citation for published version:

Adeloye, D, Harhay, MO, Ayepola, OO, Dos Santos, JP, David, RA, Ogunlana, OO, Gadanya, M, Osamor, VC, Amuta, AO, Iweala, EE, Auta, A & Rebbeck, TR 2018, 'Estimate of the incidence of bladder cancer in Africa: A systematic review and Bayesian meta-analysis', *International Journal of Urology*.
<https://doi.org/10.1111/iju.13824>

Digital Object Identifier (DOI):

[10.1111/iju.13824](https://doi.org/10.1111/iju.13824)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

International Journal of Urology

Publisher Rights Statement:

This is the author's peer-reviewed manuscript as accepted for publication.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



**An estimate of the incidence of bladder cancer in Africa: a systematic review and
Bayesian meta-analysis**

Davies Adeloye^{1,*}, Michael O. Harhay^{2,3*}, Olayemi O. Ayepola⁴, Jhonathan P. R. Dos Santos⁵, Rotimi A. David⁶, Olubanke O. Ogunlana⁷, Muktar Gadanya⁸, Victor C. Osamor⁹, Ann O. Amuta¹⁰, Emeka E. Iweala⁷, Asa Auta¹¹, Timothy R. Rebbeck¹²

1. Centre for Global Health Research, Usher institute, University of Edinburgh, UK
2. Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine University of Pennsylvania Philadelphia, Pennsylvania, USA
3. Palliative and Advanced Illness Research (PAIR) Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
4. Department of Biological Sciences, Covenant University, Ota, Nigeria
5. Department of Genetics, University of São Paulo, Brazil
6. Department of Urology, Morriston Hospital, Abertawe Bro Morgannwg University Health Board, Swansea, UK
7. Department of Biochemistry, Covenant University, Ota, Nigeria
8. Department of Community Medicine, Aminu Kano Teaching Hospital, Bayero University, Kano, Nigeria.
9. Computer and Information Sciences, Covenant University, Ota, Nigeria
10. Department of Health Studies, Texas Woman's University, Denton, TX, USA
11. School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Fylde Road, Preston, UK
12. Dana Farber Cancer Institute and Harvard T H Chan School of Public Health, Boston, MA, USA

* Both authors contributed equally to this manuscript.

Correspondence: Dr. Davies Adeloye, Centre for Global Health Research, Usher institute, University of Edinburgh, UK

. Email: bummyadeloy@gmail.com

Running Head: *Bladder Cancer in Africa*

Word Count: Main text (2499), Abstract (245)

Total References: 28

Figures: 5

Tables: 4

ABSTRACT

Objectives

To quantify the epidemiology of bladder cancer in Africa to guide a targeted public health response and support research initiatives.

Methods

We systematically searched publicly available sources for population-based registry studies reporting the incidence of bladder cancer in Africa between January 1980 and June 2017. Crude incidence rates of bladder cancer were extracted. A Bayesian network meta-analysis model was employed to estimate incidence rates.

Results

The search returned 1,328 studies. Twenty-two studies conducted across 15 African countries met our pre-defined selection criteria. Heterogeneity across studies was high ($I^2=98.9\%$, $p<0.001$). The pooled incidence of bladder cancer in Africa was 7.0 (95% Credible Interval [CI]: 5.8-8.3) per 100,000 population in men, and 1.8 (1.2-2.6) per 100,000 in women. The incidence of bladder cancer was consistently higher in North Africa in both sexes. Among men, we estimated a pooled incidence of 10.1 (7.9-11.9) per 100,000 in North Africa and 5.0 (3.8-6.6) per 100,000 in Sub-Saharan Africa (SSA). In women, the pooled incidence was 2.0 (1.0-3.0) per 100,000 and 1.5 (0.9-2.0) per 100,000 in North Africa and SSA, respectively. Incidence rates increased significantly among men from 5.6 (4.2-7.2) in the 1990s to 8.5 (6.9-10.1) per 100,000 in 2010.

Conclusions

This study suggests a growing incidence of bladder cancer in Africa in recent years, particularly among men and in North Africa. This study also highlights the lack of quality data sources and collection of essential clinical and epidemiological data in several African countries and this maligns public health planning.

Keywords: Africa; Bladder cancer; Schistosoma haematobium; Squamous cell carcinoma; Transitional cell carcinoma

1. Introduction

Bladder cancer is the ninth most common cancer worldwide, with an estimated 430,000 new cases and 165,000 deaths in 2012.¹ Among the leading cancer sites in Africa, there were an estimated 24,437 new cases and 13,268 deaths from bladder cancer in 2012.¹ The risks of bladder cancer appear to vary across world regions, correlating with smoking and occupational exposures to carcinogens in developed countries, and with chronic bladder urothelial irritation from *Schistosoma haematobium* infection in Africa and the Middle East.² However, this is changing as several African countries undergo social and economic development and changes. That is, while the histologic sub-type of bladder cancer in most parts of Africa has historically been squamous cell carcinoma (SCC) linked to schistosomiasis, a gradual shift to transitional cell carcinoma (TCC) linked to increased cigarette smoking and other lifestyle changes associated with urbanization and industrialization has been documented.^{3,4}

While the general awareness of cancer in Africa continues to increase,⁵ health systems are generally fractured and underfinanced and thus cancer screening services supporting early cancer diagnosis and prompt treatment are largely unavailable. For those diagnosed with cancer, a lack of subspecialty training in oncology and essential cancer medicines results in suboptimal management plans and care.⁶ Ongoing inadequate sanitation and hygiene also promote the recurrence of urinary schistosomiasis in many parts of Africa.

In the presence of suboptimal epidemiological data and limited histological data, this study seeks to systematically review and coalesce data on the incidence of bladder cancer in Africa to provide a comprehensive epidemiological report that can guide relevant research and public health policy in the region.

2. Methods

2.1 Search strategy and data sources

We systematically searched Medline, EMBASE, Global Health and African Journals Online (AJOL), the International Association of Cancer Registries (IACR) website, WHO African Region (AFRO) site, *GLOBOCAN studies*,⁷⁻⁹ “*Cancer Incidence in Five Continents (CI5) series*”,¹⁰ “*Cancer in Africa: Epidemiology and Prevention*,”⁵ and Google Scholar for population-based registry studies between January 1980 through June 2017 reporting the incidence of bladder cancer in Africa (**Table 1**). Reference lists of studies were hand-searched to ensure completeness in the data capture.

2.2 Selection criteria

Without language restriction, we included population-based registry studies as defined by IACR (registries that collect data from different sources in the population on all new cancer cases in well-defined populations)¹⁰, conducted in Africa that reported crude estimates of the incidence of the bladder cancer. For inclusion, a study had to have utilized histologically confirmed bladder cancer. We excluded hospital-based reports, studies on non-human subjects, reviews, case reports, opinions or editorials.

2.3 Data extraction

Data extraction was performed by two independent reviewers (AA and RAD) who separately screened studies against the selection criteria (Kappa = 92%). Disagreements were resolved by a third reviewer (DA). Data and other relevant information, including location, period, design, cancer registry, histological confirmation of diagnosis, data collation methods, coding criteria, data ascertainment and modality with which population or person years at risk

were generated, mean age (or age range), cancer cases, and crude incidence were extracted from each study.

2.4 Quality criteria

Studies were assessed for five quality measures (supplementary material):

1. The cancer registration process, which grades how the cancer registries collated and ascertained their data.
2. The coding criteria employed across studies was also reviewed to determine if the cancer types were reported according to the primary anatomic site (topography) or cellular characteristics (morphology—histology, behaviour, and grade) using the international classification of diseases (ICD) and oncology (ICD-O) guidelines.¹¹⁻¹³
3. How population or person-years at risk was generated in each study.
4. Whether the population covered in each study was representative of the target (subnational) and,
5. national populations.

Each criterion was scored *one* (1), with studies graded as *high* (4-5), *moderate* (2-3) or *low* (0-1) quality (see **Table S1**). The quality assessment has been employed in another study.¹⁴

2.5 Data analysis

A Bayesian network meta-analysis model^{15,16} was used to estimate the pooled incidence rates of bladder cancer per 100,000 population from the raw data. This model was selected due to the lack of data across calendar years, age groups, African regions and countries. This modeling approach created hierarchical models and included several covariates without leading to biases due to over-fitting the data. This is possible as the model is based on a combination of information obtained from the bladder cancer data extracted (the likelihood) with a previous

known or subjective knowledge (the prior) to generate an update on the process under investigation (the posterior probability). In this approach, we used an extension of the random effects model¹⁷ on the Bayesian meta-analysis models using uninformative priors (i.e., the prior was subjective as this was based on a balance of available data). From the Bayesian model, we extracted a posterior of plausible estimates as contained within the posterior interval 0.05 to 0.95, and averaged them to generate the posterior mean estimate. The posterior mean estimates corresponded to the pooled incidence rates of bladder cancer, and were obtained by averaging over each strata of the posterior distribution of the expectation of likelihood function respectively for all Africa (sorted by sex), African regions, countries, study period, and mean age of the patients. By doing this, we have eliminated all non-plausible values from the tails of the distribution, and averaged only those within the values of the credible interval (CI). To verify that the fit of the Bayesian model appropriately summarizes cancer explanatory variables as contained in our data set, we conducted a posterior predictive check using (i) graphical inspection of the posterior distribution of the model or nodes effects; (ii) graphical inspection of the observed data and the one generated by the model (marginal distribution of the response variable); (iii) Bayesian tests to verify if the moments of the observed data matches those generated by the model; and (iv) the Watanabe-Akaike or widely applicable information criterion 2 (WAIC2),¹⁸ which is a numerical metric used to measure the predictive accuracy of a fitted Bayesian model, with a lower WAIC2 score indicating better prediction or model fit.¹⁸ All statistical analyses were conducted using the package *rstan* (probabilistic programming language) in the R programming language (see **Supporting methods**).¹⁹

3. Results

3.1 Search results

The literature search returned a total of 1,328 publications. Out of these, 1,321 publications were from four databases: PubMed (n=537), EMBASE (n=612), Global Health (n=164) and AJOL (n=8). After all of the studies had been collated and duplicates removed, 812 records remained. Based on article screening, a further 726 studies were excluded, leaving a total of 86 full text manuscripts to be assessed. After applying the selection criteria, 64 studies were excluded (46 articles did not specify study designs and/ or clarify cancer registration process, and 18 studies did not define catchment population). A total of 22 studies were retained for this study (**Figure 1, Supporting references**).

3.2 Study characteristics

The retained 22 studies were conducted across 15 African countries, with 8 studies retrieved from North Africa, Central Africa (1), East Africa (4), Southern Africa (4), and West Africa (5) (**Table 2**). Study period across all studies ranged from 1986 to 2010. The mean age across studies ranged from 36.8 years to 61 years, with subjects mostly in the 50-59-year age group (60%), followed by the 40-49-year age group (30%). Fifteen studies (68%) were graded as high quality (**Table S1**).

3.3 Bayesian network modelling

Significant associations were observed between incidence of bladder cancer and increasing age, gender and African sub-region ($\text{Prob} > F = 0.0003$, adjusted R-squared = 39.7%). All the Bayesian networks models showed agreement with the scale of the observed datasets (**Figure 2 and Figure 3**) however we used Model 6 presented in the supplement due to the model fit statistics (Table 3, i.e. has the lowest WAIC2 score), to generate the reported estimates (**Figure S1**).

3.4 Pooled incidence rate of bladder cancer in Africa

3.4.1 Continent-wide

Across African regions, variations were observed in the reported incidence of bladder cancer, with high heterogeneity estimated across studies ($I^2=98.9\%$, $p<0.001$). The pooled crude incidence of bladder cancer in Africa was significantly higher among men compared to women, with incidence estimated at 7.0 (95% CI: 5.8-8.3) per 100,000 population per year in men, and 1.8 (95% CI: 1.2-2.6) per 100,000 in women (**Table 4**).

3.4.2 Regions

The incidence of bladder cancer was consistently higher in North Africa in both sexes. Among men, we estimated a pooled incidence of 10.1 (95% CI: 7.9-11.9) per 100,000 in North Africa and 5.0 (95% CI: 3.8-6.6) per 100,000 in Sub-Saharan Africa (SSA). In women, the pooled incidence was 2.0 (95% CI: 1.0-3.0) per 100,000 and 1.5 (95% CI: 0.9-2.0) per 100,000 in North Africa and SSA, respectively. Among men in SSA, Southern Africa had a relatively higher incidence at 7.1 (95% CI: 4.7-9.7) per 100,000 followed by West Africa at 4.5 (95% CI: 2.9-7.3) per 100,000, while the incidence in Central, and East Africa were 3.8 (95% CI: 0.9-9.4), and 3.5 (95% CI: 2.7-5.4) per 100,000, respectively. Among women, the incidence across SSA sub-regions were comparable, with Central, East, Southern and West Africa having 1.3 (95% CI: 0.4-2.5), 1.7 (95% CI: 1.1-2.5), 1.5 (95% CI: 0.8-2.6), and 2.0 (95% CI: 1.3-2.9) per 100,000, respectively (**Table 4, Figure 4 and Figure 5**).

3.4.3 Time-trends and age-groups

Among men, the incidence of bladder cancer increased from 5.6 (95% CI: 4.2-7.2) in the 1990s to 8.5 (95% CI: 6.9-10.1) per 100,000 in 2010. Among women, a minimal decrease in incidence was observed over the same period. Meanwhile, increase in bladder cancer incidence was also observed with advancing age among men, with incidence increasing from 4.8 (95% CI: 1.9-11.9) per 100,000 among persons aged 30-39 years to 13.3 (95% CI: 9.7-15.5) per 100,000

among persons aged 60 years and above. The incidence rates were however comparable between these age groups among women (**Table 4**).

4. Discussion

This study assembled a range of diverse datasets, mainly population-based cancer registries, to provide continent-wide and sub-regional estimates of bladder cancer in Africa. Our findings show a significantly higher incidence of bladder cancer among men (7.0 per 100,000) compared to women (1.8 per 100,000). This approximately 4:1 disparity in disease incidence has been observed in other settings and cohort studies.^{1,20} In addition, our estimates, which use a different statistical method, are comparable to the 2012 GLOBOCAN estimates where the male and female bladder cancer incidence was 6.3 and 2.1 per 100,000 population, respectively,²¹ (Table 4). This sex difference is presumably driven to some extent by differences in cigarette smoking, although the rates of cigarette smoking is rapidly increasing among both sexes across Africa,²²⁻²⁴ as there does not appear to be a sex-specific difference in the likelihood of *S. hematobium* infection.^{4,25} Dobruch et al²⁶ reported that several biologic and epidemiologic factors underlie gender differences in bladder cancer incidence, although women, despite a relatively lower incidence rate, particularly present with advanced tumours at diagnosis and higher mortality rates owing to delays in urologic evaluations. Meanwhile, we observed an increase in the incidence of bladder cancer among men from 5.6 to 8.5 per 100,000 between 1990 and 2010.

We noted a consistently higher bladder cancer incidence in North Africa in both sexes. Our estimates again are similar to those reported by GLOBOCAN²¹ and the Global Burden of Disease (GBD) collaborators.²⁷ For example, in 2012, GLOBOCAN estimated a bladder cancer incidence at 15.1 and 3.0 per 100,000 among men, and 3.2 and 1.6 per 100,000 among

women, for North Africa and SSA, respectively;²¹ and the GBD collaborators also estimated an overall incidence of bladder cancer at 8.3 and 5.3 per 100,000, respectively, for the two regions²⁷ (Table 4). Indeed, bladder cancer incidence rates in SSA have been reported as among the lowest in the world, but the North African estimates are actually comparable with incidence rates obtained in Europe (18.0 per 100,000), Middle East (17.2 per 100,000), and the Americas (12.9 per 100,000).^{1,21} Bladder cancer is regarded as the most common malignancy in Egypt, constituting over 30% of cancers.²⁸ The higher rates in Egypt, and North Africa generally, has been linked to the proximity with the Nile delta region where *S. Hematobium* infection is widespread, and increased cigarette smoking.²⁵ In contrast to other world regions, South-East Asia and Western Pacific regions reportedly have lower bladder cancer incidence at 2.0 and 3.5 per 100,000, respectively.²¹

A strength of this paper is a breakdown of cancer incidence across SSA regions, study periods, and age groups, which to the best of our knowledge, is the first study on bladder cancer incidence offering such detail. We found that the Southern Africa region had a relatively higher bladder cancer incidence at 7.1 per 100,000, compared to other SSA regions. While there are no clearly comparable estimates, Antoni et al¹ noted that women from Malawi had the second highest incidence rate of bladder cancer in their study at 9.2 per 100,000. The reasons for these regional differences in SSA are not clear, however the presence of several riverine communities favouring breeding of *Schistosoma* species appear to be a key factor.²⁵

Owing to its association with schistosomiasis and the inability of African countries to effectively halt the breeding and transmission of *Schistosoma* species, bladder cancer has been called a 'neglected tropical disease'.^{25,29} Although the World Health Organization supported the Schistosomiasis Control Initiatives (SCI) introduced across African states in 2002, the programme has been ineffective in many SSA regions due to incomplete drug distribution resulting in insufficient population coverage, particularly of infants and pre-school children who

suffer disproportionately from *Schistosoma* infection.²⁹ Primary prevention may be the cheapest and most effective public health response to bladder cancer in Africa, particularly by intensifying eradication programmes for schistosomiasis through widespread praziquantel therapy, provision of portable water and appropriate sanitation measures.

Suboptimal control of primary exposures for bladder disease is further confounded by an absence of widespread population-based cancer screening programmes. This contributes to a late presentation of cases, usually marked with a low probability of curative treatment.⁴ Many urology centres still lack basic cystoscopy equipment, and there are limited skilled personnel and training facilities to support 'basic' surgeries like the transurethral resection of bladder tumor (TURBT).^{2,20}

Despite attempts to provide a representative and comprehensive report on the incidence of bladder cancer in Africa, the lack of data from many countries remain a major limitation of this study. Moreover, many studies were conducted in sub-national population-based cancer registries, mainly covering provinces, districts or major cities within a country. This is even marked in Central Africa with only one study selected from this region. These geographic and demographic differences are reflected in our estimate of heterogeneity ($I^2 > 98\%$, $p < 0.001$). Further, variations in study designs, cancer registration, coding and abstracting, and the estimation of cancer incidence are important sources of heterogeneity which hinder several active disease assessment efforts. Another important source of heterogeneity may be due to the differences in tumor subtypes (SCC/TCC), which we could not ascertain from the available data. Moreover, we could not specifically describe smoking prevalence and rates of schistosomiasis infection across population groups and how these relate to variations in bladder cancer incidence in African sub-regions. Another limitation of this study is the inability to estimate age-standardized rates of bladder cancer incidence on the continent. This is mainly due to the lack of data on age from many studies. We could also have missed some important findings by

excluding hospital-based studies, however, considering that several hospital-based reports do not clearly define population covered or person-years at risk, we believe including these studies may affect the overall representativeness of our estimates.

These limitations aside, our findings offer the closest possible representation of the incidence of bladder cancer in Africa considering available data. To augment the contribution of our work, we have provided all our data to support future efforts by others. It is our hope that these findings may encourage policy redirection and resource allocation towards improved primary prevention, early diagnosis, improved research and capacity building targeted at bladder cancer on the continent.

Conflicts of interest statement: The authors declare that they have no conflicts of interests.

Role of the funding source: There was no funding source for this study. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Ethics committee approval: This study did not involve any human subjects or animals. All data is from published or summaries of completed data collections.

REFERENCES

1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. *European urology* 2017; **71**(1): 96-108.
2. Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A. International variations in bladder cancer incidence and mortality. *European urology* 2014; **66**(1): 59-73.
3. Felix AS, Soliman AS, Khaled H, et al. The changing patterns of bladder cancer in Egypt over the past 26 years. *Cancer causes & control : CCC* 2008; **19**(4): 421-9.
4. Heyns CF, van der Merwe A. Bladder cancer in Africa. *The Canadian journal of urology* 2008; **15**(1): 3899-908.
5. International Agency for Research on C. Cancer in Africa: epidemiology and prevention. *IARC scientific publications* 2003; (153): 1-414.
6. Jacobs BL, Montgomery JS, Zhang Y, Skolarus TA, Weizer AZ, Hollenbeck BK. Disparities in bladder cancer. *Urologic oncology* 2012; **30**(1): 81-8.
7. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; **127**(12): 2893-917.
8. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *International journal of cancer* 2015; **136**(5): E359-86.
9. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. *Int J Cancer* 2001; **94**(2): 153-6.
10. Bray F, Ferlay J, Laversanne M, et al. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. *International journal of cancer* 2015; **137**(9): 2060-71.
11. World Health Organization. International classification of diseases for oncology (1st ed). Geneva: WHO; 1976.
12. IARC. International classification of diseases for oncology: morphology. Bethesda MD: National Cancer Institute; 1987.
13. Percy CL, Van Holten V, Muir CS. International classification of diseases for oncology (2nd ed). 2nd ed. Geneva: WHO; 1990.
14. Adeloye D, Sowunmi OY, Jacobs W, et al. Estimating the incidence of breast cancer in Africa: a systematic review and meta-analysis. *J Glob Health* 2018; **8**(1): 010419.
15. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis, Third Edition. Boca Raton, Florida: Chapman & Hall/CRC; 2014.

16. Josse J, van Eeuwijk F, Piepho H-P, Denis J-B. Another Look at Bayesian Analysis of AMMI Models for Genotype-Environment Data. *Journal of Agricultural, Biological, and Environmental Statistics* 2014; **19**(2): 240-57.
17. DerSimonian R, Laird N. Meta-Analysis in Clinical Trials. *Controlled Clinical Trials* 1986; **7**: 177-88.
18. Watanabe S. Asymptotic Equivalence of Bayes Cross Validation and Widely Applicable Information Criterion in Singular Learning Theory. *J Mach Learn Res* 2010; **11**: 3571-94.
19. Carpenter B, Gelman A, Hoffman MD, et al. Stan: A Probabilistic Programming Language. 2017 2017; **76**(1): 32.
20. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. *European urology* 2016.
21. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *International journal of cancer* 2015; **136**(5).
22. World Health Organization. WHO report on the global tobacco epidemic, 2015. Available at: http://apps.who.int/iris/bitstream/10665/178574/1/9789240694606_eng.pdf. Geneva: World Health Organization; 2015.
23. Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. *JAMA* 2014; **311**(2): 183-92.
24. Sreeramareddy CT, Pradhan PM, Sin S. Prevalence, distribution, and social determinants of tobacco use in 30 sub-Saharan African countries. *BMC Med* 2014; **12**: 243.
25. Fedewa SA, Soliman AS, Ismail K, et al. Incidence analyses of bladder cancer in the Nile delta region of Egypt. *Cancer epidemiology* 2009; **33**(3-4): 176-81.
26. Dobruch J, Daneshmand S, Fisch M, et al. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. *European urology* 2016; **69**(2): 300-10.
27. Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. *JAMA oncology* 2016.
28. el-Mawla NG, el-Bolkainy MN, Khaled HM. Bladder cancer in Africa: update. *Seminars in oncology* 2001; **28**(2): 174-8.
29. Adenowo AF, Oyinloye BE, Ogunyinka BI, Kappo AP. Impact of human schistosomiasis in sub-Saharan Africa. *Brazilian Journal of Infectious Diseases* 2015; **19**(2): 196-205.
30. Newton R, Ngilimana PJ, Grulich A, et al. Cancer in Rwanda. *International journal of cancer* 1996; **66**(1): 75-81.

TABLES

Table 1. Search terms for studies on bladder cancer in Africa

Table 2. Study characteristics

Table 3. Comparative data score statistics of the Bayesian models

Table 4. Pooled incidence rate of bladder cancer in Africa

FIGURES

Figure 1. Flow chart of study selection.

Figure 2. Bayesian modelling showing matched data distribution (Men)

Figure 3. Bayesian modelling showing matched data distribution (Women)

Figure 4. Pooled bladder cancer incidence by African region

Figure 5. Pooled bladder cancer incidence by African country

SUPPORTING INFORMATION

Table S1. Quality Assessment and Grading

Supporting methods. This supporting text provides additional information regarding the development and estimation of the Bayesian Network model.

Figure S1. Final Bayesian Networks used to produce the estimates provided in the main manuscript.

Supporting references. Citations for the 22 studies included in the meta-analysis.

PRISMA Checklist. We provided the completed responses to the 27 checklist items that pertain to the content of a systematic review and meta-analysis.

Table 1. Search terms for studies on bladder cancer in Africa (MEDLINE)*

| # | Searches |
|----|---|
| 1 | africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ or central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial guinea/ or gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/ or somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ or sierra leone/ or togo/ |
| 2 | exp vital statistics/ or exp incidence/ |
| 3 | (incidence* or prevalence* or morbidity or mortality).tw. |
| 4 | (disease adj3 burden).tw. |
| 5 | exp "cost of illness"/ |
| 6 | exp quality-adjusted life years/ |
| 7 | QALY.tw. |
| 8 | Disability adjusted life years.mp. |
| 9 | (initial adj2 burden).tw. |
| 10 | exp risk factors/ |
| 11 | 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 |
| 12 | exp bladder cancer/ |
| 13 | 1 and 11 and 12 |

**Search terms are for MEDLINE. Searches in other databases are relatively similar.*

TABLE 2. Study characteristics

| <i>Author*</i> | <i>Country</i> | <i>Study period</i> | <i>African region</i> | <i>Registry</i> | <i>Registry data collation methods</i> | <i>Quality grading</i> | <i>Cases (male)</i> | <i>Incidence rate/100000 (male)</i> | <i>Cases (female)</i> | <i>Incidence rate/100000 (female)</i> |
|--------------------------|----------------|---------------------|-----------------------|---|---|------------------------|---------------------|-------------------------------------|-----------------------|---------------------------------------|
| <i>Echimane et al.</i> | Cote d'Ivoire | 1995-1997 | West | Abidjan Cancer Registry (population-based) | Data were actively collated from public and private hospitals and pathology laboratories | Moderate | 23 | 2.2 | 18 | 1.8 |
| <i>Bah et al.</i> | Gambia | 1988-1997 | West | Gambia National Cancer Registry (population-based) | Data were actively collated from public and private hospitals and pathology laboratories | High | 21 | 1 | - | - |
| <i>Sighoko et al.</i> | Gambia | 1998-2006 | West | National Population-based Cancer Registry | Data were actively collated from public and private hospitals and pathology laboratories | High | 29 | 0.9 | 8 | 0.21 |
| <i>Koulibaly et al.</i> | Guinea | 1992-1995 | West | Guinea Cancer Registry (population-based) | Active search for cancer cases in public and private hospitals, pathology services, and autopsy reports | Moderate | 25 | 3.8 | 7 | 0.9 |
| <i>El Mistiri et al.</i> | Libya | 2003 | North | Benghazi Cancer Registry | Active searching of hospitals, public and private laboratories, and death certificates | High | 49 | 11.7 | 6 | 1.3 |
| <i>El Mistiri et al.</i> | Libya | 2004 | North | Benghazi Cancer Registry | Active searching of hospitals, public and private laboratories, and death certificates | High | 59 | 12.4 | 16 | 4.5 |
| <i>Banda et al.</i> | Malawi | 1994-1998 | South | Malawi National Cancer Registry (population-based) | Combination of active and passive methods of case finding. The registry receives copies of reports on all cancer cases diagnosed in a central pathology laboratory, registry staff regularly visit inpatient wards and oncology outpatient clinics of national hospital, and seven other private and faith-based hospitals in the district. | Moderate | 36 | 4.3 | 3 | 0.3 |
| <i>Somdyala et al.</i> | South Africa | | South | Population-based cancer registry of the Eastern Cape Province, South Africa | Active and passive case finding of new cancer cases across health centres, district and referral hospitals and their laboratories | High | 9 | 0.6 | 7 | 0.3 |
| <i>Missaoui et al.</i> | Tunisia | 1993-2006 | North | The population-based cancer registry of the centre of Tunisia | Proactive data collection from the pathology units of the public and private medical centres, and the departments of Radiotherapy, Oncology and Haematology of the | High | 478 | 18.5 | 4 | 0.2 |

| | | | | | | | | | | |
|----------------------------------|-----------|-----------|---------|---|---|----------|-----|------|-----|------|
| | | | | | University Hospital of Sousse | | | | | |
| <i>Parkin et al.</i> | Uganda | 1991-2006 | East | Kampala Cancer Registry (population-based) | Data collected from several sources within Kyadondo county-- screening pathology reports from government hospitals and private pathology laboratories; and conducting regular searches for cancer cases admitted or treated in hospitals. | High | 134 | 2.9 | 81 | 1.6 |
| <i>Wabinga et al.</i> | Uganda | 1991-1997 | East | Kampala Cancer Registry (KCR) | Active and passive case finding of new cancer cases across public and private hospitals and pathology laboratories | High | 13 | 2.5 | - | - |
| <i>Wabinga et al.</i> | Uganda | 1991-2010 | East | Kampala Cancer Registry (KCR) | Active and passive case finding of new cancer cases across public and private hospitals and pathology laboratories | High | 10 | 2.9 | - | - |
| <i>Chokunonga et al.</i> | Zimbabwe | 1993-1995 | South | Zimbabwe National Cancer Registry | Data collated from all public and private hospitals and pathology laboratories | High | 62 | 8.9 | 39 | 6.9 |
| <i>Basset et al.</i> | Zimbabwe | 1990-1992 | South | Zimbabwe National Cancer Registry (population-based) | Data are collected from all hospital services in the city, from pathology laboratories (public and private), and from death certificates. | High | 68 | 13.2 | 43 | 12.5 |
| <i>Bayo et al.</i> | Mali | 1987-1998 | West | Population cancer registry in Bamako, Mali | Data collated from all public and private hospitals and pathology laboratories | High | 23 | 7.5 | 12 | 3.2 |
| <i>Newton et al³⁰</i> | Rwanda | 1991-1994 | Central | Population-based cancer registry in the southern prefecture of Butare, Rwanda | Active and passive case finding of new cancer cases across public and private hospitals and pathology laboratories | Moderate | 5 | 0.9 | 3 | 0.4 |
| <i>Manraj et al.</i> | Mauritius | 1989-1993 | East | National cancer registry | Systematic registration of cancer cases identified from central laboratory of Hospitals, admissions registers and discharge résumés | Moderate | 114 | 4.4 | 44 | 1.7 |
| <i>Fedewa et al.</i> | Egypt | 1999-2002 | North | Gharbiah Population-Based Cancer Registry | Collated from relevant health institutions across the region | High | 977 | 13.7 | 232 | 3.2 |
| <i>Bouchbika et al.</i> | Morocco | 2005-2007 | North | Casablanca Registry | Greater Casablanca Cancer Registry | Moderate | 368 | 6.7 | 52 | 0.9 |
| <i>El Mistiri et al.</i> | Libya | 2003-2005 | North | Benghazi Cancer Registry | Active searching of hospitals, public and private laboratories, and death certificates | High | 174 | 15.2 | 26 | 2.3 |
| <i>Hamdi Cheriff et al.</i> | Algeria | 1986-2010 | North | Population-based Cancer Registry of Setif | Active searching of hospitals, public and private laboratories, and death certificates | High | 262 | 10.3 | 34 | 1.2 |

| | | | | | | | | | | |
|----------------------|---------|-----------|-------|--|---|----------|-----|------|---|---|
| <i>Hsairi et al.</i> | Tunisia | 1993-1997 | North | Cancer registries of the regions of the North, Sousse and Sfax | Active search of hospital and laboratory registers in the three regions | Moderate | 276 | 10.7 | - | - |
|----------------------|---------|-----------|-------|--|---|----------|-----|------|---|---|

Note: Data reported for the last year of study (or single site) when pooled data is not available for multiple year (or site) studies, *see **Supplementary material** for references.

Table 3. Comparative data score statistics of the Bayesian models

| Sex | Model s | p-values (max) | p-values (min) | p-values (median) | p-values (mean) | p-values (sd) | Eff. N. of parameters | WAIC 2 |
|-------|------------|-------------------|-------------------|----------------------|--------------------|------------------|--------------------------|-----------|
| Men | Model-1 | 0.4 | 0.6 | 1.0 | 0.9 | 0.2 | 4.5 | 137.5 |
| | Model-2 | 0.4 | 0.7 | 1.0 | 0.9 | 0.1 | 5.3 | 140.9 |
| | Model-3 | 0.4 | 0.7 | 1.0 | 0.9 | 0.1 | 6.7 | 138.7 |
| | Model-4 | 0.5 | 0.6 | 1.0 | 0.9 | 0.3 | 5.3 | 138.1 |
| | Model-5 | 0.5 | 0.6 | 1.0 | 0.8 | 0.4 | 9.7 | 132.5 |
| | Model-6 | 0.5 | 0.6 | 0.9 | 0.8 | 0.4 | 28.4 | 118.0 |
| Women | Model-1 | 0.2 | 0.8 | 1.0 | 1.0 | 0.3 | 4.7 | 96.9 |
| | Model-2 | 0.2 | 0.7 | 1.0 | 1.0 | 0.2 | 5.0 | 96.5 |
| | Model-3 | 0.1 | 0.8 | 1.0 | 1.0 | 0.2 | 4.9 | 95.1 |
| | Model-4 | 0.3 | 0.8 | 1.0 | 1.0 | 0.4 | 4.5 | 92.8 |
| | Model-5 | 0.3 | 0.7 | 1.0 | 0.8 | 0.3 | 7.7 | 77.2 |
| | Model-6 | 0.4 | 0.7 | 0.8 | 0.7 | 0.4 | 15.5 | 70.0 |

Note: WAIC2- Watanabe-Akaike or widely applicable information criterion, showing the predictive accuracy of the fitted Bayesian model, with a lower WAIC2 score indicating better prediction ¹⁸.

Table 4. Pooled incidence rate of bladder cancer in Africa

| Data | Regions | Men (incidence per 100,000) | | Women (incidence per 100,000) | | | | | |
|----------------|---------------|--------------------------------------|--------------------------------|-------------------------------|----------------------|--------------------------------------|--------------------------------|------------------------------|----------------------|
| | | Current study | | GLOBOCA N 2012 estimate | GBD 2015 estimate | Current study | | GLOBOCAN 2012 estimate | GBD 2015 estimate |
| | | Posterior mean estimate* (95% CI) | I ² (%), p value | | | Posterior mean estimate* (95% CI) | I ² (%), p value | | |
| Africa | Africa | 7.0 (5.8-8.3) | 99.0, 0.000 | 6.3 | - | 1.8 (1.2-2.6) | 95.8, 0.000 | 2.1 | - |
| African Region | North | 10.1 (7.9-11.9) | 99.4, 0.000 | 15.1 | 13.9 | 2.0 (1.0-3.0) | 97.3, 0.000 | 3.2 | 2.6 |
| | SSA | 5.0 (3.8-6.6) | 95.0, 0.000 | 3.0 | 7.9 | 1.7 (1.1-2.5) | 94.2, 0.000 | 1.6 | 3.2 |
| | Central | 3.9 (0.9-9.4) | - | 2.2 | - | 1.3 (0.4-2.5) | - | 1.3 | 2.9 |
| | East | 3.5 (2.7-5.4) | 72.8, 0.000 | 3.3 | 6.1 | 1.7 (1.1-2.5) | 0.0, 0.748 | 2.0 | 2.7 |
| | South | 7.1 (4.7-9.7) | 97.7, 0.000 | 7.5 | 13.3 | 1.5 (0.8-2.6) | 96.1, 0.000 | 1.9 | 5.1 |
| | West | 4.5 (2.9-7.3) | 89.0, 0.000 | 2.1 | 8.5 | 2.0 (1.3-2.9) | 89.0, 0.000 | 1.3 | 3.2 |
| Year | 1980-1989 | 6.9 (4.7-9.6) | 96.6, 0.000 | - | - | 2.8 (1.0-4.9) | 93.2, 0.000 | - | - |
| | 1990-1999 | 5.6 (4.2-7.2) | 99.5, 0.000 | - | - | 1.6 (1.0-2.6) | 97.0, 0.000 | - | - |
| | 2000-2010 | 8.5 (6.9-10.1) | 99.0, 0.000 | - | - | 1.8 (0.9-2.7) | 95.8, 0.000 | - | - |
| Age | 30-39 | 4.8 (1.9-12.0) | 86.5, 0.000 | - | - | 1.9 (1.1-3.3) | - | - | - |
| | 40-49 | 3.5 (1.9-6.5) | 98.7, 0.000 | - | - | 1.7 (0.9-2.6) | 93.8, 0.000 | - | - |
| | 50-59 | 7.4 (5.9-8.9) | 36.8, 0.208 | - | - | 1.9 (1.1-2.8) | 96.6, 0.000 | - | - |
| | 60-69 | 13.4 (9.7-15.5) | 99.0, 0.000 | - | - | - | 95.8, 0.000 | - | - |
| Country | Algeria | 6.4 (3.3-10.4) | 99.8, 0.000 | 10.8 | 5.5 | 1.2 (0.2-2.5) | - | 1.5 | 1.7 |
| | Cote d'Ivoire | 4.8 (1.9-12.0) | - | 1.7 | 5.0 | 1.9 (1.1-3.3) | - | 0.5 | 4.1 |
| | Egypt | 12.4 (7.2-15.4) | - | 21.8 | 22.4 | 2.0 (1.0-3.2) | - | 5.6 | 4.1 |
| | Gambia | 2.6 (0.9-7.6) | 0.0, 0.744 | 1.1 | 4.4 | 1.5 (0.5-2.7) | - | 0.5 | 1.8 |
| | Guinea | 4.6 (2.5-8.9) | - | 1.4 | 10.2 | 1.6 (0.8-2.8) | - | 0.5 | 2.2 |
| | Libya | 12.6 (9.3-14.0) | 47.0, 0.152 | 15.3 | 28.4 | 2.0 (1.0-3.1) | 71.5, 0.30 | 2.3 | 4.0 |
| | Malawi | 4.8 (2.7-8.7) | - | 8.4 | 17.4 | 1.3 (0.4-2.5) | - | 5.9 | 8.0 |
| | Mali | 7.4 (4.3-10.4) | - | 7.5 | 16.6 | 2.8 (1.0-4.9) | - | 6.0 | 5.8 |
| | Mauritius | 5.0 (2.9-8.7) | - | 7.7 | 9.4 | 1.7 (1.0-2.8) | - | 1.8 | 2.5 |
| | Morocco | 6.9 (4.2-10.3) | - | 10.8 | 12.7 | 1.8 (0.9-3.0) | - | 1.3 | 3.2 |
| | Rwanda | 3.9 (0.9-9.4) | - | 4.8 | 5.7 | 1.3 (0.4-2.5) | - | 2.5 | 2.3 |
| | South Africa | 4.4 (0.8-10.8) | - | 8.2 | 12.5 | 1.5 (0.5-2.7) | - | 2.0 | 4.9 |
| | Tunisia | 10.4 (5.0-15.5) | 98.1, 0.000 | 15.3 | 18.7 | 1.8 (0.6-3.1) | - | 1.7 | 2.0 |
| | Uganda | 3.0 (2.3-5.1) | 0.0, 0.862 | 0.4 | 6.2 | 1.6 (0.7-2.7) | - | 1.3 | 2.8 |
| | Zimbabwe | 9.5 (5.2-12.9) | 79.2, 0.028 | 2.8 | 20.4 | 1.7 (0.8-3.0) | 84.5, 0.011 | 3.0 | 7.7 |

*posterior mean est. corresponds to the incidence of bladder cancer estimated in the current study